DexCom, Inc. - DXCM STOCK NEWS

DexCom, Inc. (Nasdaq: DXCM) reported a 25% revenue growth in Q1 2022, reaching $628.8 million. U.S. revenue rose 18% while international revenue surged 43%. GAAP operating income was $41.3 million (6.6% of revenue), down from the previous year. The company reaffirmed its 2022 revenue guidance of $2.82 - 2.94 billion and outlined strategic initiatives, including the limited launch of the Dexcom G7 in Europe and new market expansions. Cash reserves stood at $2.69 billion, providing strong financial flexibility.

DexCom, the leader in continuous glucose monitoring (CGM), introduced its new product portfolio at the ATTD conference, showcasing the Dexcom ONE, Dexcom G6, and the FDA-reviewed Dexcom G7. These systems aim to enhance diabetes management with features like real-time monitoring and customizable alerts. The Dexcom ONE is now accessible in Spain and will launch in the UK this May. The offerings emphasize innovation and connectivity, designed to cater to diverse diabetes needs.

DexCom, Inc. (NASDAQ:DXCM) announced that its new Dexcom ONE Continuous Glucose Monitoring System will launch in the UK this May. Currently under review for addition to the NHS Drug Tariff, this system aims to enhance accessibility for diabetes management. The NICE has recommended offering glucose sensors to Type 1 diabetes patients based on individual needs, promoting better health outcomes. Dexcom ONE features a user-friendly app for real-time glucose monitoring, reducing the need for fingerpricks and improving treatment decisions.

DexCom, Inc. (NASDAQ:DXCM) announced plans to release its first quarter 2022 financial results after the market closes on Thursday, April 28, 2022. A conference call will be held at 4:30 p.m. (ET) to discuss the results, with a live webcast available on the investor relations website.

DexCom, based in San Diego, California, is a leader in continuous glucose monitoring systems, aiming to improve diabetes management globally.

Dexcom, Inc. (NASDAQ:DXCM) announced a four-for-one forward stock split, pending stockholder approval for an increase in authorized shares from 200 million to 800 million. If approved, each share outstanding on May 19, 2022, will split into four shares. The split-adjusted trading is set to commence on June 10, 2022. This action aims to enhance stock liquidity and accessibility for investors. Further details will be provided in the Preliminary Proxy Statement filed with the U.S. Securities and Exchange Commission on March 25, 2022.

DexCom (NASDAQ:DXCM) has received CE Mark approval for its Dexcom G7 Continuous Glucose Monitoring (CGM) system, enhancing diabetes management for users aged two and older in Europe. The Dexcom G7 features the market's fastest sensor warmup at 30 minutes, a compact design, and a redesigned mobile app that integrates Dexcom Clarity. This system eliminates the need for fingersticks, providing real-time glucose data directly to smart devices. DexCom plans to launch the G7 in Europe shortly, further solidifying its leadership in real-time CGM technology.

Dexcom announced CE Mark approval for its G7 Continuous Glucose Monitoring (CGM) System, enhancing diabetes management for users in Europe aged two years and older, including pregnant women. The G7 is designed to be more powerful and user-friendly, with a 30-minute sensor warmup time, no fingersticks required, and real-time glucose readings sent to compatible devices. The system reduces blood sugar fluctuations and increases time in range, supporting better health outcomes.

Dexcom, Inc. (NASDAQ: DXCM) received approval from the Ontario government for coverage of its Dexcom G6 CGM System through the Assistive Devices Program, effective March 14, 2022. This initiative benefits individuals with type 1 diabetes over the age of 2 who meet specific criteria, expanding access to this innovative glucose monitoring technology. Ontario joins six other provinces in offering public coverage for continuous glucose monitoring, enhancing diabetes management and potentially reducing long-term health complications.